

Haematologica
HAEMATOL/2018/196295
Version 3

Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study

Eduard J. van Beers, Stephanie van Straaten, D. Holmes Morton, Wilma Barcellini, Stefan W. Eber, Bertil Glader, Hassan M. Yaish, Satheesh Chonat, Janet L. Kwiatkowski, Jennifer A. Rothman, Mukta Sharma, Ellis J Neufeld, Sujit Sheth, Jenny M. Despotovic, Nina Kollmar, Dagmar Pospisilova, Christine M. Knoll, Kevin Kuo, Yves D. Pastore, Alexis A. Thompson, Peter E. Newburger, Yaddanapudi Ravindranath, Winfred C. Wang, Marcin W. Wlodarski, Heng Wang, Susanne Holzhauer, Vicky R. Breakey, Madeleine Verhovsek, Joachim Kunz, Melissa A. McNaull, Melissa J. Rose, Heather A. Bradeen, Kathryn Addonizio, Anran Li, Hasan Al-Sayegh, Wendy B. London, and Rachael F. Grace

Disclosures: RFG, HMY, JAR, EJN, WB, BG, SWE, EJvB, KK, YR, SC, JLK are scientific advisors to Agios Pharmaceuticals. RFG, EJvB, BG, HMY, DHM, KK, JLK, YR, SS, and WB receive research funds from Agios Pharmaceuticals. The remaining authors declare no competing financial interests. The Pyruvate Kinase Deficiency Natural History Study was supported by research funding from Agios Pharmaceuticals.

Contributions: RFG, EJvB, and SvS conceived the study, analyzed and interpreted the data, and wrote the manuscript. DHM, WB, SWE, BG, HMY, SC, JLK, JAR, MS, EJN, and SS conceived the studies, interpreted the data and provided critical revisions to the manuscript. JDM, NK, DP, CMK, KK, YDP, AAT, PEN, YR, WCW, MWW, HW, SH, VRB, MV, JK, MAM, MJR, HAB, and KA performed the research and contributed to the manuscript. AL, HAS, WBL analyzed and interpreted the data and contributed to the manuscript.